Who is sponsoring NCT03866668?

NCT03866668 is sponsored by Stanford University.

What condition does NCT03866668 study?

NCT03866668 studies Autism, Autism Spectrum Disorder.

What is the status of NCT03866668?

NCT03866668 is currently RECRUITING.

Last reviewed 2025-11-08 · How we verify

An Open-Label Pilot Study of Esomeprazole in Children With Autism

NCT03866668 Phase 2 RECRUITING

Autism is a pervasive developmental disorder characterized by core deficits in social behavior and communication and the presence of repetitive/stereotyped behaviors. The objective of the study is to evaluate the efficacy of Esomeprazole as a treatment for social communication deficits in children with Autism Spectrum Disorder (ASD). This prospective 12 week open-label study will invite 25 children with ASD between the ages of 2 and 6 years of age to participate.

Details

Lead sponsor	Stanford University
Phase	Phase 2
Status	RECRUITING
Enrolment	25
Start date	2019-05-29
Completion	2028-12

Conditions

Autism
Autism Spectrum Disorder

Interventions

Esomeprazole

Primary outcomes

Change from Baseline on the Social Responsiveness Scale, 2nd Edition (SRS-2) — Baseline, 4 Weeks, 8 Weeks
Social Responsiveness Scale (SRS) raw scores measure social abilities with lower raw scores meaning better social abilities. (Raw Score Range: 0 - 195)

Countries

United States